Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHui Chen
About this trial
The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is:
Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)?
Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.
Eligibility criteria
Qualifiers
1. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.
Disqualifiers
1. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,400 Participants
are grouped into 2 trial groupsSponsors and collaborators
Hui Chen
Lead sponsor
Beijing Friendship Hospital
Sponsor institution
Source ClinicalTrials.gov